New antibiotic combo tested against superbugs in hospitals

NCT ID NCT07176247

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tracks 100 hospital patients with hard-to-treat bacterial infections who receive the antibiotic combination aztreonam-avibactam. Researchers will measure how often the infection clears up without needing more antibiotics. The goal is to see how well this drug works in real-world settings, outside of strict clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Aztreonam-avibactam (antibiotic combination)

What this could lead to

If successful, this could confirm that aztreonam-avibactam is a reliable treatment option for multidrug-resistant infections in critically ill patients.

What could go wrong

This is an observational registry, not a controlled trial, so results may be less definitive. The drug may not work for all resistant bacteria, and side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CRITICAL CARE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infections infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • French Society of Intensive Care (SRLF)

    Paris, France